Midwest Biosolutions–Bionter: analytical instruments, 202305– collab Midwest Bio to promote + sell Bionter products + services in the US

	Period	2023-05-08
	Region	United States (USA)
	Partner, 1st	Midwest Biosolutions Corporation
	Partner, 2nd	Bionter AG
	Product	EVE particle counter
	Product 2	business services
	Person	London, Jeff (Midwest Biosolutions 202305)
	Person 2	Schrems, Angelika (Bionter 202305 Global Head of Business Development)

Bionter AG. (5/8/23). "Press Release: Bionter Announces Partnership Agreement with Midwest Biosolutions to Drive Market Growth in the US". Basel.

Bionter, an innovative analytical technology provider, is excited to announce its partnership agreement with Midwest BioSolutions, a prominent sales agency in the US market. The collaboration aims to drive market growth and expand the reach of Bionter’s products and services in the Biopharma industry in the US.

Through this partnership, Midwest Bio will utilize its extensive network and expertise to promote and sell Bionter’s products and services to Biopharma customers across the US. The agreement will enable Bionter to tap into Midwest Bio’s knowledge of the US Biopharma landscape and benefit from its sales and marketing strategies to enhance its market presence and drive growth.

“We are thrilled to partner with Midwest Bio to accelerate our growth in the US market,” said Angelika Schrems, Global Head of Business Development of Bionter. “Their extensive network and expertise in the Biopharma industry will enable us to expand our reach and better serve our global customers with sites in the US.”

The partnership agreement will focus on driving sales growth, developing marketing strategies, and expanding the reach of Bionter’s products and services in the US market. The collaboration will enable Bionter to access new market segments, enhance its customer base, and drive revenue growth.

“Partnering with Bionter is a fantastic opportunity for us to leverage our expertise in Biopharmaceutical manufacturing and complement our current portfolio to drug product testing and provide a broader solution portfolio to our existing clients,” said Jeff London, CEO of Midwest Bio. “We are so excited to enter into this partnership with Bionter and to introduce their superior technologies to North America.”

This partnership agreement is a testament to the commitment of both companies to drive innovation for Biopharmaceutical manufacturers. Stay tuned for more updates as Bionter and Midwest Bio work together to achieve their goals.

For media inquiries, please contact Angelika Schrems at bd@bionter.com.

About Bionter:

Bionter is a Swiss-based Biotech start-up. Since the foundation in 2020, Bionter has established successful prototype testing with global Pharma companies, received successful seed funding from the US investor Dynamk Capital and launched their first product in Europe and the US. The team has significant experience in particle analytics as well as the commercialization of analytical testing products. Bionter’s first product, EVE, is a fully automated particle counter, that works non-destructive with the sample used and is fully compliant with current regulations.

Bionter is a premium supplier of analytical testing solutions and contributes to the benefit of people’s health by helping pharma companies and their service providers to bring drugs faster and safer to the market.

About Midwest Bio:

Midwest Biosolutions is a US-based manufacturer’s representative group established in 2004. With a team of seasoned business development professionals, they have helped numerous industry-leading, global suppliers establish thriving direct-to-end user sales in the US pharmaceutical/biopharma market. Their knowledge of process applications combined with a vast network of industry contacts, allows them to provide a uniquely experienced perspective to both the suppliers they represent and the customers they support.